B-cell acute lymphoblastic leukemia · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Mercaptopurine, Methotrexate, WB-XRT Variant #01 | — | R 7 811 | 84d | — | — | ~1 | ~R 7 811 indirect | — |
Methotrexate and Pegaspargase N/A - intrathecal component Partial | — | R 1 014 | 42d | — | — | ~1 | ~R 1 014 indirect | — |
2 of 2 regimens shown